Drugs / RAD402
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07259213 | Mar 2026 → Nov 2028 expected | castration-resistant prostate carcinoma | Radiopharm Theranostics, Ltd | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-10-20 | Radiopharm Theranostics, Ltd | Results Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs radiopharmtheranostics.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-10-20 | Radiopharm Theranostics, Ltd | Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs radiopharmtheranostics.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RAD402 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07259213 ↗ |
| Known as | 161Tb-RAD402 | “161Tb-RAD402, a Radiolabeled Anti-Kallikrein-Related Peptidase 3 (KLK3) Monoclonal Antibody” NCT07259213 ↗ |
| Modality | Monoclonal antibody | “161Tb-RAD402, a Radiolabeled Anti-Kallikrein-Related Peptidase 3 (KLK3) Monoclonal Antibody” NCT07259213 ↗ |
| Target | KLK3 | “Anti-Kallikrein-Related Peptidase 3 (KLK3) Monoclonal Antibody Targeting Free Prostate-Specific Antigen” NCT07259213 ↗ |